# VIE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vie

- Industry: Consumer Products
- Headquarters: Kamakura-shi, Japan
- Website: www.viestyle.co.jp
- Total disclosed funding: $2.5M
- Latest round: Series A (Mar 6, 2024)
- Investors on record: 10

## About

Based in Kanagawa, Japan, and founded in 2013, VIE, Inc., formerly known as VIE STYLE, Inc., developed a wearable device that can acquire brain waves from the ear (external auditory canal) using an ear tip as an electrode, earphones with music generated from brain waves, and a meditation experience support tool using earphone-type electroencephalograms. In March 2024, VIE, Inc. raised venture debt financing.

VIE offers a range of products and services, including VIE Zone/VIE Chill, which leverages earphone-type sensors to accurately capture various biological data, such as brain waves, stress levels, and fatigue. The data analyzed using proprietary AI algorithms to provide users with insights into their cognitive and emotional states. VIE utilizes neurotechnology to visualize and analyze brain waves, enhancing well-being through pleasant stimulation with music and other forms of entertainment.

The company plans to use the March 2024 funding to strengthen research and business development systems through recruitment, create technology seeds, and develop hardware.

## Funding rounds

- Series A, Mar 6, 2024, $1.5M — PE&HR, Taisho Pharmaceutical Co., Ltd., Murata Manufacturing Company, Otsuka Holdings Co., Ltd., KAYAC Inc., TOWA PHARMACEUTICAL
- Series A, Jan 13, 2022, $0.9M — Shizuoka Capital, Shizuoka Bank, FinTech Global Incorporated, AIX Tech Ventures Inc.

## Investors

- Shizuoka Capital (https://capitalatlas.ai/funds/shizuoka-capital) — Series A
- Shizuoka Bank — Series A
- FinTech Global Incorporated — Series A
- AIX Tech Ventures Inc. — Series A
- PE&HR (https://capitalatlas.ai/funds/pe-hr) — Series A
- Taisho Pharmaceutical Co., Ltd. — Series A
- Murata Manufacturing Company — Series A
- Otsuka Holdings Co., Ltd. — Series A
- KAYAC Inc. — Series A
- TOWA PHARMACEUTICAL — Series A